OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
January 01, 2005
Sponsored and produced by Focus Limited.
Citing cherry-picked patients, unrealistic dosing, and placebo control, payers will increasingly require that the proof for payment of drugs must come from head-to-head trials.
Heading the WHO list are pandemic influenza and antibiotic-resistant bacterial infections. Together the two could kill millions.